Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Window of Opportunity Study of Intratumoral CD40 Agonist (Mitazalimab) With or Without PD-1 Inhibitor (Nivolumab) in Patients With Resectable Breast Cancer (WINIT-BC)

Next Previous
Trial Profile

Window of Opportunity Study of Intratumoral CD40 Agonist (Mitazalimab) With or Without PD-1 Inhibitor (Nivolumab) in Patients With Resectable Breast Cancer (WINIT-BC)

Status: Not yet recruiting
Phase of Trial: Phase 0

Latest Information Update: 24 Feb 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mitazalimab (Primary) ; Nivolumab (Primary)
  • Indications Breast cancer
  • Focus Adverse reactions
  • Acronyms WINIT-BC

Most Recent Events

  • 18 Feb 2026 Planned End Date changed from 1 Jan 2033 to 1 Mar 2033.
  • 18 Feb 2026 Planned primary completion date changed from 1 Jan 2028 to 1 Mar 2028.
  • 18 Feb 2026 Planned initiation date changed from 1 Jan 2026 to 1 Mar 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top